BIOXCEL THERAPEUTICS INC. - COMMON STOCK

BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia

25 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference

28 May 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

21 May 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Reports First Quarter 2024 Financial Results

09 May 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024

25 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting

24 Apr 2024 10:30:24 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential

22 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia

10 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces $25 Million Registered Direct Offering

25 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine

15 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023

12 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

01 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Termination of Proposed Public Offering

13 Feb 2024 09:00:43 By Nasdaq GlobeNewswire

BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)

12 Feb 2024 07:14:31 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Proposed Public Offering

08 Feb 2024 16:01:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA®

06 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of Dexmedetomidine

05 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today

12 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs

11 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023

30 Nov 2023 07:00:00 By Nasdaq GlobeNewswire